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Introduction
Secreted cytokines transmit messages between cells to initiate defensive immune responses and to promote 
tissue homeostasis during immune resolution (1, 2). These extracellular cytokines can be regulated by clear-
ance or can be inactivated via sequestration by soluble cytokine receptors (3). Circulatory soluble cytokine 
receptors are produced by a number of  mechanisms, including proteolytic shedding of  the membrane cyto-
kine receptors and alternative gene splicing (4). Soluble cytokine receptors retain the abilities to recognize 
and bind their corresponding cytokines, similarly to their membrane-bound forms, and function as decoy 
receptors to attenuate cytokine concentrations. Modification of  the cytokine-mediated immune response 
by soluble cytokine receptors provides feedback control of  cytokine activities.
Dysregulated production of soluble cytokine receptors to overtly dampen cytokine activities has been 
observed in diseases (5, 6). In recent serum proteomic studies, soluble ST2 (sST2) was identified as a prognostic 
biomarker found to be elevated in patients with heart failure and cardiovascular-related death (7–9), acute car-
diac allograft rejection (10), inflammatory bowel disease (8, 11), and graft-versus-host disease (GVHD) (12–17). 
Among patients receiving allogeneic hematopoietic cell transplantation (HCT), elevated sST2 levels in patients 
with steroid-refractory GVHD is the factor most significantly associated with their subsequent non–relapse-
related death (12). This observation has been validated across multiple transplant platforms (12, 18–20).
sST2 is the soluble form of  the membrane-bound ST2 (hereafter referred to as ST2) (21) encoded by 
interleukin-1 receptor–like 1 (IL1RL1) (22, 23). Both sST2 and ST2 share the same extracellular domain 
(ECD) (22, 24) that bind with the only known ligand, IL-33 (21). ST2 is expressed mainly on hematopoietic 
cells including T helper type 2 (Th2) cells, group 2 innate lymphoid cells (ILC2), regulatory T cells (Tregs), 
and mast cells (25, 26). On ST2+ CD4+ T cells, ligation of  IL-33 with ST2 recruits IL-1R accessory protein 
(IL-1RAcP) and activates nuclear factor (NF)-κB and p38 MAP kinases via the ST2/IL-33 axis (27, 28). 
A recent mechanistic study (29) further elucidated that binding of  IL-33 with ST2 reduces ST2 mobility 
to engage additional interaction with IL-1RAcP in the IL-1RAcP–ST2–IL-33 complex. Activation of  the 
Soluble cytokine receptors function as decoy receptors to attenuate cytokine-mediated signaling 
and modulate downstream cellular responses. Dysregulated overproduction of soluble receptors 
can be pathological, such as soluble ST2 (sST2), a prognostic biomarker in cardiovascular 
diseases, ulcerative colitis, and graft-versus-host disease (GVHD). Although intervention using 
an ST2 antibody improves survival in murine GVHD models, sST2 is a challenging target for drug 
development because it binds to IL-33 via an extensive interaction interface. Here, we report the 
discovery of small-molecule ST2 inhibitors through a combination of high-throughput screening 
and computational analysis. After in vitro and in vivo toxicity assessment, 3 compounds were 
selected for evaluation in 2 experimental GVHD models. We show that the most effective 
compound, iST2-1, reduces plasma sST2 levels, alleviates disease symptoms, improves survival, 
and maintains graft-versus-leukemia activity. Our data suggest that iST2-1 warrants further 
optimization to develop treatment for inflammatory diseases mediated by sST2.
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ST2/IL-33 axis in Th2 cells causes secretion of  IL-4, IL-5, IL-13 (21, 28, 30), and IL-9 (31) that elicit the 
type 2 immune response (32). IL-33 signaling also promotes regulatory function of  ST2+ Tregs in the colon 
and restrains inflammation in a murine acute colitis model (33) and GVHD (34). Depending on the cellular 
stimuli, sST2 can be secreted by endothelial cells, fibroblasts, epithelial cells, and type 1 CD4+ and CD8+ 
T cells (34). sST2 sequesters free IL-33 to attenuate the type 2 immune response, such as in allergic airway 
inflammation (35), and can contribute to disease progression when dysregulated.
GVHD is the major life-threatening complication in patients receiving allogeneic HCT. In HCT, damage to 
recipients’ tissues, caused by preconditioning regimens, enhances the antigen-presenting cell–mediated proin-
flammatory response to donor T cells during transplantation, which contributes to GVHD development (36). At 
the early onset of GVHD, excess sST2 production dampens the type 2 immune response, disables its balanced 
control of type 1 immunity, and exacerbates disease progression (12, 34, 37). We have recently shown that thera-
peutic blockade of excess sST2 can mitigate the immune response in murine GVHD models (34). In our study 
of mice with induced GVHD, we observed an initial major sST2 production locally from intestinal stromal and 
endothelial cells in the gastrointestinal (GI) tract followed by subsequent sST2 secretion from alloreactive T 
cells. Mice that were treated with an ST2-neutralizing antibody during HCT exhibited decreased plasma sST2 
concomitant with increased plasma IL-33, decreased production of Th1 cells/cytotoxic T cells (Tc1) and Th17/
Tc17 cells, and increased ST2 expression on Th2 cells and Tregs during GVHD development (34). Although 
the ST2 antibody binds both ST2 and sST2, we reasoned that circulating ST2 antibody neutralizes the rise in 
local and systemic sST2 levels during the onset of GVHD to ameliorate GVHD progression. Displacement of  
sST2 from IL-33 by the ST2 antibody may lead to sST2 becoming prone to proteolytic degradation in the blood 
stream and decrease sST2 concentration over time. A precedent example is in the finding that association of IL-6 
and its soluble receptor prolongs their half-lives in circulation (38).
The feasibility of  using small molecules to inhibit cytokine receptors, such as ST2, to achieve thera-
peutic benefit is unknown because biologics are the traditionally used antagonists (39). Motivated by our 
findings in GVHD models using the ST2 antibody and the advantages of  small-molecule therapies over 
antibodies, including easier administration especially by the oral route, superior tissue penetration, modifi-
able pharmacokinetic properties, higher uniformity between batches, and lower manufacturing costs, we 
combined high-throughput screening (HTS) and computational analyses to discover 3 chemical series of  
small-molecule ST2 inhibitors. After toxicity evaluation, we selected 3 candidate compounds for in vivo 
studies. We found that administration of  2 compounds led to reduced sST2 levels and amelioration of  
GVHD without compromising the graft-versus-leukemia (GVL) effect in mouse models. Because the ST2/
IL-33 axis plays important roles in the pathogeneses of  other inflammatory diseases (40), therapeutics 
derived from these compounds may have applications beyond GVHD.
Results
Identifying small-molecule inhibitors of  ST2. To discover ST2 inhibitors, we have developed a biochemi-
cal AlphaLISA that measures the binding between ST2-Fc (fragment, crystallizable) and IL-33. The 
AlphaLISA was then implemented and optimized in a pilot screening of  2,727 compounds with known 
biological activity. The robustness of  the assay was determined by the Z′ factor that corresponds to a 
combination of  the signal-to-basal ratio (S/B) with the coefficient of  variation (CV). For the pilot screen-
ing, we obtained an S/B = 11 and CV = 0.7, giving a Z′ factor of  0.95 (n = 2). One hit (sappanone A) 
from the pilot screening was confirmed in secondary biochemical assays, but it was not further evaluated 
because of  its cytotoxicity to human peripheral blood mononuclear cells (hPBMCs).
For the large-scale HTS experiment, we adopted the workflow outlined in Figure 1. In the primary 
screening, 77,701 compounds from 3 commercial suppliers (ChemBridge, ChemDiv, and Analyticon 
Discovery) were tested at a single dose (17 μM) using the AlphaLISA. We obtained an average Z′ factor 
of  greater than 0.7 for all plates, and 1,823 compounds yielded inhibition of  30% or higher. To select 
a set of  diverse and representative compounds for confirmatory screening, the 1,823 compounds were 
annotated by the Molecular ACCess System (MACCS) fingerprint (41) to enable structural compari-
son in the computational analysis. Tanimoto coefficients calculated based on the fingerprints of  the 
compounds were used to quantify their structural differences, and a cutoff  Tanimoto coefficient at 0.65 
was set to cluster compounds into the same group. Each group was further inspected to remove fre-
quent binders (found in either PubChem or an internal curated database) and compounds containing 
substructures alerted in the pan-assay interference compounds (PAINS) (42). Remaining compounds 
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amenable to further chemical modifications were selected after consultation with medicinal chemists. 
These computer-based compound analyses led to the selection of  45 representative compounds for 
secondary confirmatory evaluation, and we found that 14 of  the 45 compounds gave dose-dependent 
titrations. In addition to the AlphaLISA, we used another confirmatory Thermofluor assay to identify 
4 compounds of  the 14 that showed direct binding activities to 2 constructs of  our recombinant ST2 
proteins, as indicated by positive shifts in protein unfolding temperature (Figure 1).
To examine the specificity of  the 14 compounds for ST2/IL-33 inhibition, we employed the human 
IL-33 sensor cells HEK-Blue IL-33 cells (InvivoGen). HEK-Blue IL-33 cells were generated by stable 
transfection of  HEK293-derived cells with the human IL1RL1 gene to overexpress ST2 on the cell 
membrane. This modification was augmented by blockade of  the tumor necrosis factor-α (TNF-α) 
receptor and IL-1R1 on the cell membrane to permit specific receptor response to IL-33 signaling. 
Activation of  the NF-κB and AP-1 pathways transduced by the ligation of  bioactive IL-33 with ST2 on 
the HEK-Blue IL-33 cell is monitored by the amount of  the secreted embryonic alkaline phosphatase 
(SEAP) reporter proteins. In this experiment, we also included TNF-α ligand to confirm the inactivity 
of  the TNF-α receptor pathway as a negative control. In the HEK-Blue IL-33 cell–based assay, 10 of  
the 14 compounds gave 40% or greater inhibition at 17 μM.
Based on the data of  these assays, 4 hits (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.99208DS1) were selected as the basis for the 
subsequent ligand- and receptor-based computer screening in the hits enrichment study. In the ligand-based 
approach, we aligned the 3-D structures of  the 4 hits to determine the common pharmacophore features 
and their distance relationship. A 4-feature pharmacophore model was then used as a filter to search com-
mercial compound libraries. In the receptor-based screening, we performed a structure-based screening 
against the IL-33 binding site in ST2 (see Methods) using an indole surrogate library from Chem-X-Infinity. 
These analog searches led to selecting 118 additional candidates for activity evaluation. Among them, 12 
Figure 1. Flowchart of integrated high-throughput screening and computational analysis for discovery of ST2 
inhibitors. PAINS, pan-assay interference compounds; MACCS, Molecular ACCess System; hPBMC, human peripheral 
blood mononuclear cell.
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compounds exhibited dose-dependent titration, giving IC50 value ranges of  17.97–95.08 μM in the Alpha-
LISA and 23.9–76.5 μM in the HEK-Blue assay. Inhibition activities of  the extensive list of  initial hits and 
their analogs have recently been published in a patent (WO 2017083242A1).
In vitro and in vivo toxicity evaluation of  selected candidates. To select compounds suitable for in vivo evalu-
ation, we first assessed the acute toxicity of  17 compounds (including 12 compounds identified from hits 
enrichment) in an in vitro assay using hPBMCs. After 10 hours of  incubation at 3 concentrations (7.4–66 
μM), 10 compounds killed 10% or less of  hPBMCs at 22.2 μM, and 6 of  them killed less than 20% of  
hPBMCs at 66 μM (Figure 2A), which is comparable to the control, citalopram (a serotonin transporter 
inhibitor and a false positive identified from the pilot screening). Structurally, the 6 less toxic compounds 
can be classified into 3 distinct chemotypes (I–III in Supplemental Figure 2), of  which chemotype III com-
pounds contain a quincoridine core derived from natural products. Despite their lower in vitro toxicity, we 
reasoned that the thione group of  CB6141343 in chemotype I may be prone to oxidation during in vivo 
metabolism. CB6141343 was replaced by iST2-1 and CD4170-0776 discovered from analog searching. For 
compounds in chemotype II, we found that iST2-2 has improved solubility relative to CD3573-0071 and 
another analog of  iST2-2, iST2-3, was also included for comparison. The IC50 values of  iST2-1 determined 
by the AlphaLISA and the HEK-Blue assay were 56.14 and 54.62 μM, respectively, and for iST2-2, they 
were 122 and 25.93 μM, respectively (Figure 2B). Notably, iST2-3 was 2-fold more potent than iST2-2 
in both assays (Figure 2A). iST2-4 from chemotype III had IC50 values of  17.57 μM (AlphaLISA) and 
25.92 μM (HEK-Blue) (Figure 2B). Ultimately, 7 compounds from 3 chemotypes (Supplemental Figure 
2) were chosen for the 16-day in vivo dose escalation toxicity study in which mice were treated with each 
compound at 5, 10, 20, or 40 mg/kg on days 1, 4, 9, and 12. Only CD4170-0776 showed toxicity in mice 
starting at 10 mg/kg (Figure 2C) and was subsequently eliminated. For the remaining 6 compounds, only 
iST2-3 showed toxicity to mice at a higher dose (one mouse died after treatment with 40 mg/kg iST2-3 on 
day 12). Using the in vitro microsomal stability assay, we also found that iST2-1, 2, 3, and 4 can undergo 
quick first-passage clearance in vivo in mice (Supplemental Table 3). We anticipated that they would have 
acceptable toxicity and low accumulation in mice over extended periods of  time.
Determination of  the functional groups that contribute to the inhibitory activity of  iST2-1. Among the 3 repre-
sentative compounds in Figure 2B, the commercially acquired iST2-1 and iST2-2 are racemic mixtures that 
contain 2 stereospecific isomers (Figure 3A). To identify important functional groups of  our ST2 inhibitors 
that produced their activities, we studied iST2-1 because of  its higher potency and synthetic feasibility. We 
first synthesized racemic iST2-1, (S)-iST2-1, (R)-iST2-1, and analogs of  racemic iST2-1 shown in Figure 3A. 
In our AlphaLISA, we obtained an IC50 value of  47.7 ± 5 μM (n = 5) for racemic iST2-1, which is close to 
56.14 μM of the commercially procured iST2-1. Based on the same assay, (R)-iST2-1 and (S)-iST2-1 had IC50 
values of  43.0 ± 15.1 and 42.0 ± 11.5 μM (n = 2), respectively, which are comparable to that of  the racemic 
iST2-1 within curve fitting errors (Figure 3B). Using racemic iST2-1 as a reference, we found that replacement 
of  the nitroso group in iST2-1 with a smaller fluorine atom (iST2-1-1F), a carboxylic acid (iST2-2), an amide 
group (iST2-3), or a cyano group (iST2-4) all reduce the inhibition constant by 2- to 5-fold. Removal of  the 
methoxy group of  iST2-1 gave iST2-5, which had a higher IC50 value at 97.56 ± 28.2 μM (n = 2), too. The 
structure-activity relationship of  select iST2-1 analogs showed that the nitroso and methoxy groups in iST2-1 
contribute to its activity and warrant further exploration in inhibitor optimization.
Studies of  the binding interaction between iST2-1 and ST2. Currently, no cocrystal structures of  ST2 with 
iST2-1 or any small molecule are available. We and other groups (43, 44) have previously shown that the D3 
domain in the ST2 ectodomain (ST2ECD-D3), anchored by a preceding linker region to the D2 domain, exhibits 
high mobility in apo-ST2 (the ligand-free ST2). Our computational studies of  IL-1R1 and ST2 also indicated 
that the ectodomain of  cytokine receptors may possess conformations that can be modulated by allosteric 
inhibitors (44, 45). To investigate if  iST2-1 imposed allosteric inhibition in solution, we conducted small-angle 
X-ray scattering (SAXS) studies. In Figure 3C, we show that the SAXS profile of  ST2ECD/iST2-1 is close 
to that of  apo-ST2ECD. The Kratky plot in Figure 3C indicated that ST2ECD/iST2-1 retains the asymmetric 
globular shape of  apo-ST2ECD except a slight increase at 0.05 < q < 0.15 attributable to the addition of  iST2-1 
to apo-ST2ECD. Although the calculated pair-wise distance distribution, P(r), of  ST2ECD/iST2-1 differs from 
that of  apo-ST2ECD, comparison of  their reconstructed ab initio shape functions indicated that iST2-1 binding 
made minor modifications to the overall shape of  apo-ST2ECD (Figure 3D). Analysis of  the SAXS profiles 
gave radius of  gyration (Rg) values of  31.38 and 31.26 Å for apo-ST2 and ST2
ECD/iST2-1 (Supplemental 
Table 1), suggesting similar conformational states between them. The same analysis also gave lower esti-
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mated molecular weights (MWs) of  42.4 and 42.8 kDa for apo-ST2 and ST2ECD/iST2-1 than those (between 
43.9 to 44.8 kDa) determined by liquid chromatography-mass spectroscopy (LC-MS) analysis for apo-ST2ECD 
(Supplemental Figure 3). Taken together, the SAXS studies suggest that binding of  iST2-1 to ST2ECD causes 
small changes to the conformational flexibility of  ST2 (46, 47) and may not restrict the mobility of  ST2ECD-D3.
To determine potential (R)- and (S)-iST2-1 binding sites in ST2ECD, we employed unbiased molecular 
dynamics (MD) simulations. The binding site detection is enhanced by a modified cosolvent MD simula-
tion method (cMD) (48) that embeds ST2ECD in an environment that is high in (R)-iST2-1 or (S)-iST2-1 
concentration. The high inhibitor concentration increases the encounter probability between the inhibi-
tor and different binding sites in ST2ECD simultaneously during the simulations. This implementation 
overcomes the need to perform lengthy and multiple MD simulations by placing a single inhibitor in 
random positions relative to the protein in simulations (49). After the encounter between inhibitors and 
putative binding sites in ST2ECD, the stronger ST2ECD–inhibitor interaction will theoretically retain the 
inhibitor at the sites for a longer time compared with transient association. To detect recurring (or con-
sensus) binding sites, 2 different simulation conditions were performed (see Methods).
Because the SAXS data indicated that iST2-1 may not modulate the conformation of  ST2ECD-D3, we 
focused our analyses of  iST2-1–binding sites on the D1 and D2 domains of  ST2 (ST2ECD-D1D2). ST2ECD-D1D2 
accounts for 83% of  the binding free energy between ST2 and IL-33 and contains potential small-molecule-
binding sites (44). We found that iST2-1 resides persistently in multiple locations on ST2ECD during the 32 
ns of  simulation time. Consensus sites include S1r, and S2r for (R)-iST2-1, and S1s for (S)-iST2-1 shown in 
Figure 3E. Although S1r, located between the D2 and D3 domains of  ST2, coincides with small-molecule-
binding hotspots characterized in our previous study (44), 2 other consensus sites are not at the interaction 
interface between ST2 and IL-33. At the ST2/IL-33 interaction interface, 3 non–consensus binding sites 
Figure 2. In vitro and in vivo toxicity evaluation of selected candidates. (A) Human PBMC death induced by compounds at 3 concentrations after incuba-
tion for 20 hours (duplicate per compound at each concentration). IC50 values determined by the AlphaLISA are shown in parentheses. Compounds belong-
ing to chemotypes I, II, and III and unclassified are grouped together. CB6114052, CB5107562, and NAT13-343201 are 3 initial hits. The average IC50 values 
of 17 compounds at 63.7 μM were used as references for setting the maximum concentration at 66 μM. (B) Titration curves for iST2-1, iST2-2, and iST2-4 
measured with the AlphaLISA and the HEK-Blue IL-33 assay. (C) In vivo dose-escalation toxicity evaluation of 7 selected compounds in healthy mice. Data 
represent mean ± SEM (n = 3 per compound). hPBMC, human peripheral blood mononuclear cell.
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of  (R)-iST2-1 (S3r) and (S)-iST2-1 (S2s, S3s) were also identified that may directly inhibit the association 
between ST2 and IL-33 (Figure 3, E and F). To examine if  the force-field parameters and glycosylation 
of  ST2ECD may affect the ST2ECD conformation to exclude these detected binding locations of  iST2-1, we 
performed additional simulations using the monoglycosylated ST2ECD resolved in the ST2/IL-33 structure 
with the most recent force-field parameters and studied 2 additional chiral structures of  iST2-1 related to 
Figure 3. IC50 values of iST2-1 and its analogs, SAXS studies of apo-ST2, ST2/iST2-1, and potential iST2-1 binding sites identified from computational 
simulations. (A) Chemical structures of racemic iST2-1, (R)-iST2-1, (S)-iST2-1, analogs of iST2-1, and structural alignment of (R)-iST2-1 (purple) with (S)-iST2-1 
(green). IC50 values of the inhibitors are shown in parentheses. (B) Inhibition curves and IC50 values (in parentheses) of 4 representative compounds. Each data 
point is an average of triplicate measurements ± SD. (C) SAXS profiles, the residual plot between the SAXS profiles of apo-ST2 and ST2/iST2-1, comparison 
of the Kratky plot based on the SAXS profiles of apo-ST2 and ST2/iST2-1, the pair-wise distance distribution [P(r)] of apo-ST2 and ST2/iST2-1 calculated from 
the SAXS profiles. Dmax values are shown in parentheses. (D) Ab initio shape reconstruction of apo-ST2 (gray) and ST2/iST2-1 (purple). (E) Mapping of the (R)-
iST2-1 and (S)-iST2-1 binding sites (surface envelop) in ST2 based on 32-ns MD simulations. Maps detected from 13- and 15-Å octahedron boxes are colored in 
purple and green, respectively. Consensus binding sites (S1r, S2r and S1s) are circled. The D1 and D2 domains of ST2 are labeled. (F) Binding sites of (R)-iST2-1 
(green mesh) and (S)-iST2-1 (red mesh) that block interaction between ST2 and IL-33 (orange) are highlighted. (G) Binding sites of (R)-, (S)-, (S,S)-iST2-1 in the 
glycosylated ST2 from the MD simulations. (S,S)-iST2-1 is (S)-iST2-1 in which the proton on the pyrrolidine group is in the S form and its mapped site is shown 
in cyan mesh. SAXS, small-angle X-ray scattering.
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the protonation of  the pyrroline group in iST2-1. We confirmed that (R)-iST2-1, (S)-iST2-1, and (S,S)-
iST2-1 bind preferentially to S3r and S2s sites (Figure 3G). Because S3r and S2s are in close proximity, 
whether (R)-iST2-1 and (S)-iST2-1 compete for a same binding site remains to be determined.
ST2 inhibitors decrease IFN-γ–producing T cell populations in the in vitro mixed lymphocyte reaction assay. To 
examine the utility of  our ST2 inhibitors in GVHD, we first evaluated iST2-1, iST2-2, and iST2-4 (Figure 
2B), representing 3 different chemotypes, in the in vitro human mixed lymphocyte reaction (MLR) assay. 
In the MLR, purified CD4+ and CD8+ T cells from a healthy donor (responder) are mixed with irradiated T 
cell–depleted PBMCs from a second healthy HLA-mismatched donor (stimulator) to model alloreaction of  
T cells responding to alloantigens in vitro (50, 51). Similar to GVHD, the T cells’ alloreactivity in the MLR 
can induce sST2 secretion to dampen Th2 activity and shift T cell polarization to Th1. In the DMSO control, 
we observed continued replication/proliferation of  CD4+IFN-γ+ (2.25%) and CD8+IFN-γ+ (17.9%) T cells 
after 7 days in the MLR. In the MLR incubated with iST2-1 from 1 to 10 μM, dose-dependent reduction of  
CD4+IFN-γ+ (1.51% → 0.32%) and CD8+IFN-γ+ (15.6% → 1.57%) T cell populations were observed (Supple-
mental Figure 4A). Although iST2-4 was more potent than iST2-1 in biochemical and cell-based assays, it 
was less effective at reducing the IFN-γ+ T cell population. Relative to the DMSO control, the least potent 
compound, iST2-2, only reduced the CD4+IFN-γ+ T cell population by 39% at 10 μM, whereas 86% and 81% 
reductions in the CD4+IFN-γ+ T cell population were observed in the iST2-1– and iST2-4–treated groups, 
respectively. Treatment with any of  the 3 ST2 inhibitors maintained the beneficial FoxP3+CD4+ Treg popula-
tion compared with DMSO control (Supplemental Figure 4B). In vitro MLR assay data demonstrated that 
our ST2 inhibitors ─ by potentially blocking the sequestration of  IL-33 by sST2 ─ attenuated Th1/Tc1 cell 
proliferation compared with DMSO control while maintaining the Treg population.
ST2 inhibitors reduce plasma sST2 levels, alleviate GVHD, and improve survival in vivo. After assessing the in vivo 
toxicity results, the MLR data, and the feasibility of procuring the compounds in a timely manner, 3 racemic 
compounds ─ iST2-1, iST2-2, and iST2-3 ─ were selected for testing in 2 experimental GVHD disease models. 
In the first xenogeneic model, 106 T cells extracted from hPBMCs (hu-T cells) were transplanted into NOD-scid 
IL2Rgammanull (NSG) mice preconditioned with 300 cGy total body irradiation (TBI) on day –1. In the second 
minor HLA-mismatched model, 2 × 106 T cells and 5 × 106 bone marrow (BM) cells from C57BL/6 (B6) mice 
were transplanted into C3H.SW mice that received 1,100 cGy TBI on day –1. Mice in both models received 
twice daily intraperitoneal (i.p.) injections of ST2 inhibitors (iST2-1, 41.4 mg/kg/day; iST2-2, 18 mg/kg/day; 
and iST2-4, 20.5 mg/kg/day) or DMSO as control for 21 days starting from day –1 to day 20 (Figure 4A). In the 
hu-T cells → NSG model, we examined the effects of ST2 inhibitors on human T cell differentiation, whereas in 
the B6 → C3H.SW model, the impact of ST2 inhibitors on mouse T cell polarization was measured.
Ex vivo analysis showed that iST2 inhibitor treatment did not change the number of infiltrating T cells in the 
gut, which is the main direct GVHD target organ, compared with control in the B6 → C3H.SW model (Figure 
4B). In both models treated with iST2-1 and iST2-2, we observed a reduction in CD4+IFN-γ+ T cells and an 
increase in FoxP3+CD4+ Tregs at day 14 after HCT (Figure 4C and Supplemental Figure 5). In the B6 → C3H.
SW model, the iST2-1 and iST2-2 treatment groups also showed decreases in both the Th1 (CD4+T-bet+) and 
Th17 (CD4+RORγt+) cell populations. On day 21, the iST2-1 treatment group showed effective control of the 
CD4+IFN-γ+ T cell population, at only 2.5% in the hu-T cells → NSG model and 40% in the B6C3H.SW model 
compared with CD4+IFN-γ+ T cell populations of 20% and 70% with the DMSO control, respectively (Figure 
4, D and E, and Supplemental Figure 6). Increases in the FoxP3+CD4+ Treg population (Supplemental Figure 
7) were also observed in mice treated with iST2-1 compared with the DMSO control in both the xenogeneic and 
minor HLA-mismatched models (10% versus <1% in the hu-T cells → NSG model and 10% versus 2% in the 
B6 → C3H.SW model). A 2-fold increase in CD4+ IL-4–secreting cells was found in the iST2-1 treatment group 
compared with the DMSO control (Supplemental Figure 7). Although CD8+ T cells can drive the GVHD pro-
gression in the B6 → C3H.SW model, we found that CD8+ T cells were present at low frequency in the gut and 
did not seem to drive the pathogenicity of sST2 in the gut. CD8+ T cells detected in the gut showed no significant 
differences between the ST2-inhibitor-treated and control groups on day 21 (Supplemental Figure 8). Consistent 
with the in vitro MLR experiment, in vivo iST2-2 treatment was less effective at limiting CD4+IFN-γ+ T cell 
proliferation and increasing the FoxP3+CD4+ Treg population over time.
Two important biomarkers (plasma levels of  sST2 and IFN-γ) indicative of  GVHD progression were 
monitored in this study. In the hu-T cells → NSG model, we measured human sST2 and IFN-γ levels to 
determine the response of  human T cells. In both models, increases in both biomarkers were found at day 
7 or later (Figure 5A). Differential control of  both biomarker levels by ST2 inhibitors coincided with the 
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Figure 4. Dosages and treatment 
schedule for ST2 inhibitors and ex 
vivo analysis in the GVHD mouse 
models. (A) The dosages were calcu-
lated using the body weight of each 
mouse at 20 mg and correspond to 
twice the IC50 values of the inhibitors 
determined by the HEK-Blue IL-33 
assay. (B) Number of T cells infiltrat-
ing the gut in the B6C3H.SW GVHD 
model at day 14. Flow cytometric 
analysis of intestinal CD4+IFN-γ+ and 
FoxP3+CD4+ T cell populations on day 
14 in the (C) hu-T cells → NSG model 
and day 21 in the (D) hu-T cells → NSG, 
(E) B6 → C3H.SW GVHD models treat-
ed with iST2-1, iST2-2, or iST2-3. n = 2 
per group at day 14 and 21 respectively, 
and for each model. Data represent 
mean ± SEM (n = 2). TBI, total body 
irradiation; hPBMC, human peripheral 
blood mononuclear cell. *P < 0.05, **P 
< 0.01 by unpaired t test.
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bifurcation of  GVHD scores starting on week 2 for the hu-T cells → NSG model and week 1 for the B6 
→ C3H.SW model (Figure 5, A and B). The results in Figure 5A show that iST2-1 treatment effectively 
prevented the escalation of  sST2 levels in both models. Low levels of  sST2 were maintained up to day 28 
in the hu-T cells → NSG model and day 21 in the B6 → C3H.SW model. Plasma IFN-γ levels increased on 
day 14 in the hu-T cells → NSG model and day 7 in the B6 → C3H.SW model. The iST2-1 treatment group 
showed more than 50% lower plasma IFN-γ levels than the DMSO control or the iST2-3 treatment group. 
In comparison, the reductions in plasma sST2 and IFN-γ levels were less in mice treated with iST2-2.
Ex vivo cellular and plasma biomarker analyses showed the T cell population and GVHD-related 
biomarker changes affected by treatment with our ST2 inhibitors in 2 in vivo experimental models. In 
Figure 5B, we demonstrate that the most efficacious ST2 inhibitor, iST2-1, reduced the GVHD score to 
3.25 in the hu-T cells → NSG model and to 4 in the B6 → C3H.SW model accompanied by improved 
survival rates of  50% and 67%, respectively, on day 35. The less potent iST2-2 also reduced GVHD 
scores and improved survival rates to 25% and 50%. The adverse outcome of  iST2-3 treatment may be 
attributed to its increased toxicity to the disease-burdened mice, as suggested by the toxicity to healthy 
mice at a higher dose (Figure 2C). Taken together, our results showed that administration of  iST2-1 or 
iST2-2 reduced the plasma sST2 levels, decreased GVHD scores, and improved survival in 2 GVHD 
models, and their in vivo efficacies correlated with decrease in the level of  sST2.
iST2-1 ameliorates GVHD burden and maintains GVL effect in the murine MLL-AF9 leukemia model. The ben-
eficial T cell alloreactivity is used to induce GVL activity to eliminate residual leukemia in HCT. To investi-
gate whether treatment with iST2-1 ameliorated GVHD without diminishing the GVL effect, we studied the 
effects of  iST2-1 treatment in the B6 → C3H.SW model injected with syngeneic MLL-AF9 leukemia cells. 
iST2-1 was administered i.p. twice daily to the C3H.SW mice from day –1 to +20 after HCT. In this model, 
mice will succumb to either GVHD manifestations or leukemia without treatment. We found that animals 
treated with DMSO died of  GVHD starting on week 3 and subsequently of  leukemia for a 20% overall sur-
vival at the end of  the study on day 73 (Figure 6). In the treatment group, mice receiving iST2-1 survived past 
day 70 and were GVHD/leukemia-free. Of note, this survival benefit was higher than expected, with the sole 
GVHD protection suggesting a potential increase in antitumor activity with iST2-1 treatment, similar to what 
we have observed with ST2-neutralizing antibody treatment (34). Thus, our data showed that amelioration 
of  GVHD by iST2-1 treatment did not compromise and may have even increased the GVL benefit of  HCT.
Discussion
The curative potential of  allogeneic HCT for hematological malignancies and disorders has been limited 
by the frequent development of  GVHD detected upon clinical presentation. Proteomics-based biomarker 
discovery in GVHD (12, 17, 52–55) has now provided a means to stratify high-risk patients to receive 
aggressive disease management. Despite the progress made in prognosis, high-grade and steroid-refractory 
GVHD (56, 57) remains intractable. Biomarker studies have identified sST2 as the most significant prog-
nostic biomarker in GVHD. sST2 produced by intestinal stromal cells, epithelial cells, and Tc/Th17 cells 
(34) can antagonize and suppress Th2 cell and Treg activation, leading to an amplified proinflammatory 
phenotype in GVHD development. Our previous study (34) indicated that reducing the levels of  sST2 via 
ST2 antibody treatment can manage GVHD in mice. Small-molecule reagents capable of  blocking the 
ST2–IL-33 interaction may produce similar therapeutic benefits to mitigate GVHD development and can 
be tailored to therapies for diseases using sST2 as a biomarker.
In this work, we have integrated computational analyses with HTS to discover 3 classes of  small-
molecule ST2 inhibitors that block binding between ST2 and IL-33. In vitro and in vivo toxicity evalua-
tions provided guidance of  the selection of  compounds exhibiting low or no toxicity for testing in follow-
up disease model studies. The effects of  iST2-1, -2, and -4 from 3 chemical classes on alloreactivity in 
the MLR assay further confirmed their effectiveness for treating alloreactive T cell activity in vitro. The 
efficacies of  our ST2 inhibitors observed in 2 experimental models of  GVHD demonstrated that they 
reduce the levels of  prognostic biomarkers and Th1 cell populations. Although our biochemical assays 
were not designed to test the ability of  our compounds to inhibit mouse ST2ECD and IL-33, we hypoth-
esized that our ST2 inhibitors target mouse ST2 because mouse and human ST2ECD share 68% sequence 
identity and human ST2ECD binds to human and mouse IL-33 (58). This is supported by the evidence that 
the ST2 inhibitors produced similar effects to reduce the same prognostic biomarkers in the human T 
cells to NSG mouse model and the B6 → C3H.SW mouse GVHD model ─ where no human proteins are 
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present. Data from this second mouse GVHD model led us to further examine the influence of  the most 
effective compound, iST2-1, on the GVL effects in the same B6 → C3H.SW GVHD model. We found 
that treatment with iST2-1 maintained the beneficial GVL activity in mice receiving HCT.
Although the effects of  our ST2 inhibitors on the mouse GVHD models paralleled the findings in 
the study of  the neutralizing human ST2 antibody treatment (34), higher dosages of  ST2 inhibitors com-
pared with the human ST2 antibody were required because of  the weaker inhibitory activities of  the ST2 
inhibitors. Still, small molecules provide many attractive pharmacokinetic properties when considering 
clinical application for the treatment of  different diseases. For example, the small-molecule CCR5 inhibi-
tor, maraviroc, was used in GVHD prophylaxis to reduce lymphocyte migration in a recent phase 1/2 
trial (59), despite results showing that CCR5 antibodies were also effective in a mouse model of  GVHD 
(60). Further, sST2 is also a biomarker of  chronic GVHD (16) where small-molecule inhibitors can be 
an advantageous route for administration of  a long-term medication. Currently, the benefits of  iST2-1 in 
GVHD management remain limited by its potency; however, further optimization is feasible based on the 
structure-activity relationship of  our select iST2-1 analogs. Our investigation of  the potential binding sites 
of  iST2-1 identified locations on ST2 that can be interrogated by single-site mutagenesis and the precise 
binding mode of  iST2-1 with ST2 needs to be defined by crystal structure determination in future studies. 
Our computational binding site analysis indicated that S3r for (R)-iST2-1 and S3s for (S)-iST2-1 are in close 
proximity. An inhibitor design strategy, similar to bivalent inhibitors (61, 62), of  connecting 2 isomers of  
iST2-1 using a linker group may lead to improved inhibitor potency. In addition, the efficacy of  iST2-4, the 
third chemotype inhibitor, in the GVHD experimental models remains to be determined.
Figure 5. sST2 and 
IFN-γ levels, GVHD 
scores, and survival 
curves for GVHD 
disease model 
mice treated with 
ST2 inhibitors. (A) 
Plasma levels of 
human and murine 
sST2 and IFN-γ in 
the hu-T cells → 
NSG and B6 → C3H.
SW GVHD models 
from day 7 to 28. 
Data represent 
mean ± SEM (n = 3 
per group for NSG 
and n = 6 for C3H.
SW). (B) GVHD 
scores and survival 
curves for the hu-T 
cells → NSG and B6 
→ C3H.SW GVHD 
models. Data rep-
resent mean ± SEM 
for GVHD scores, 
and Kaplan-Meier 
curves for survival 
(n = 13 per group). 
P values were 
calculated for GVHD 
scores by unpaired t 
test and for survival 
by log-rank test. *P 
< 0.05; **P < 0.01; 
***P < 0.001.
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Cytokine receptors are an important class of  therapeutic targets; yet, only biologics are approved treatment 
options for targeting their ECDs that recognize specific cytokines. Small molecules inhibiting the interaction 
between cytokines and cytokine receptors have eluded identification because of  their extensive protein–pro-
tein interaction interface. Our data suggest the feasibility of  targeting ST2ECD with small-molecule inhibitors to 
achieve in vivo activity in experimental GVHD models. Although our ST2 inhibitors are not highly selective 
between sST2 and ST2, they yielded decreased sST2 levels and lesser severity in in vivo GVHD models. In in 
vivo systems, soluble cytokine receptors can be locally produced at high concentrations and become systemic 
after entering the circulation. We have shown that the ratio of  sST2 to ST2 is increased 40- to 70-fold in the 
intestine of  the mouse GVHD model (34), and another study showed that a high local concentration of  sST2 
within the myocardium can be induced by myocardial pressure-overload to enhance hypertrophy in mice (63). 
We interpret the specific inhibition of  sST2 observed in vivo as the action of  ST2 inhibitors on a large excess 
amount of  sST2 over ST2 expressed on T cells, similar to what we have found for inhibition with the anti-ST2 
antibodies in the same GVHD model. Spatiotemporal changes in sST2 and ST2 expression in different cells 
and tissues in the GVHD progression and their contribution to T cell activation remain to be defined. Future 
in-depth studies of  the mechanisms of  action of  our ST2 inhibitors in GVHD, including the consequences of  
their differential inhibition of  ST2 and sST2, will provide insights for further studies of  our ST2 inhibitors in 
other disease models (64–66) such as inflammatory bowel disease (67). Structurally, the ST2 transmembrane 
domain restrains the D3 domain of  ST2 to limit the conformational motion of  the D1 and D2 domains of  
ST2. In contrast, sST2, containing only the D1–D3 domains, possesses higher conformational flexibility (44) 
in blood circulation. To discover and develop sST2-selective inhibitors, differences in the conformational flex-
ibility between ST2 and sST2 may offer opportunities.
Finally, the expanding roles of  the ST2/IL-33 axis in type 2 diabetes and obesity (68), pulmonary arte-
rial hypertension (69), and idiopathic pulmonary fibrosis as well as systemic sclerosis (70, 71) suggest that 
therapeutic development of  ST2 inhibitors will have a broad impact on disease management beyond GVHD.
Methods
AlphaLISA. An AlphaLISA had been optimized in our pilot screening, including adjustment of  several 
parameters in accordance with NIH recommendations (72) at the University of  Michigan. From our pilot 
screening, the assay is robust with an S/B of  = 11, CV = 0.7%, and Z′ factor (73) of  0.95. The assay was 
adapted for HTS in the Indiana University School of  Medicine, Chemical Core Facility that has the capa-
Figure 6. GVL activity in the C3H.SW mouse model treated with DMSO or iST2-1. (A) GVHD scores. Data represent 
mean ± SEM, unpaired t test, P = 0.0001 (n = 5 per group), and (B) Kaplan-Meier survival curves of C3H.SW mice that 
received 2 × 104 GFP+ MLL-AF9 leukemia cells with allo-HCT (B6 → C3H.SW) and were treated with DMSO control (filled 
circles) or iST2-1 (open circles), log-rank P = 0.013 (n = 5 per group). The treatment schedule was the same as in Figure 
4A. (C) Percentage of mice that succumbed to GVHD or leukemia or remained alive with treatment of DMSO or iST2-1 at 
the end of the study (day 73). *P < 0.05; ***P < 0.001.
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bility to optimize and automate biochemical-based assays for screening a large library of  compounds with 
adequate diversity and representation of  chemical space. The buffer used in the assay contains 14.37 ml 
PBS, 30 μl Tween 20 (Sigma-Aldrich), and 600 μl of  5% bovine serum albumin (BSA, Gemini) in PBS. A 
mixture of  ST2 and IL-33 was prepared by adding 0.30 μl of  14.1 μM recombinant human ST2-Fc Chi-
mera (R&D Systems, 523-ST) and 0.30 μl of  55.25 biotinylated recombinant human IL-33 (United States 
Biologicals, I7663-97 with custom biotinylation) to 1.4 ml of  assay buffer. In the HTS, each well of  a 384-
well Proxi-plate (PerkinElmer) was first blocked by 100 μl of  assay buffer for 1 hour at room temperature. 
After removing the blocking buffer, 20 μl of  the ST2/IL-33 mixture was pipetted into each well and incu-
bated at room temperature for 1 hour followed by addition of  compounds at 17 μM (0.8 μl) to each well and 
incubated at room temperature for 1 hour. Ten microliters of  60 μg/ml anti-6×His-conjugated AlphaLISA 
acceptor beads (PerkinElmer) were added to each well and incubated at room temperature for 1 hour before 
addition of  10 μl of  60 μg/ml of  streptavidin-labeled AlphaLISA donor beads (PerkinElmer) for incubation 
at room temperature for 30 minutes. Incubation of  acceptor and receptor beads was conducted in dark-
ness. The well with 3 nM ST2 alone was used as a negative control, whereas the ST2/IL-33 mixture with 
a human ST2 antibody (R&D Systems, MAB523) added at 0.45 ng/μl was used as the positive control. 
Plates were read using the Envision Plate Reader (PerkinElmer).
HEK-BLUE IL-33 assay. HEK-Blue IL-33 cells purchased from InvivoGen (catalog hkb-hil33) were designed 
to detect bioactive IL-33 by monitoring activation of the NF-κB and AP-1 pathways. They were generated by 
stable transfection of HEK-Blue cells with the IL1RL1 gene. These cells express a SEAP reporter gene under the 
control of the IFN-β minimal promoter fused to 5 NF-κB and 5 AP-1 binding sites. Stimulation of HEK-Blue 
IL-33 cells with human IL-33, but not with IL-18 or TNF-α, activates the NF-κB and AP-1 pathways, trigger-
ing the production of SEAP. Levels of SEAP in the supernatant can be easily determined with QUANTI-Blue.
HEK-Blue IL-33 cells were grown at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 4.5 g/l glucose, 10% (vol/vol) fetal bovine serum (FBS), 2 mM L-glu-
tamine, 50 U/ml penicillin, 50 μg/ml streptomycin, and 100 μg/ml Normocin. Suspended cells from 
preparations were then dispensed in a 96-well plate at 190 μl/well with a density of  265,000 cells/ml in 
each well. In the NF-κB activation assay, cells were treated with 10 μl IL-33 solution at 100 ng/ml and 
50 μl of  serial dilutions of  tested compounds or DMSO (positive control). For the negative control, 10 μl 
of  TNF-α solution at 100 ng/ml was used. The final volume in each well was 250 μl. After 20 hours of  
incubation in a CO2 incubator at 37°C, 160 μl of  the cell supernatants was mixed with 40 μl of  QUANTI-
Blue (InvivoGen) in each well for 1–3 hours at 37°C before measurement of  SEAP levels using a spec-
trophotometer at 620–655 nm. Blockade of  the stimulation of  HEK-Blue IL-33 cells by recombinant 
human IL-33 was confirmed by using the neutralizing human ST2 antibody. The IC50 values of  active 
compounds were calculated based on the percentage decreases in SEAP levels with serial dilutions rela-
tive to the signals obtained from the positive and negative controls.
SAXS experiment. Procedures for expression and purification of  recombinant human ST2 (His-
TEV-ST2ECD, sequence: K19-P323) have been reported previously (44). The binding affinity between 
our recombinant human ST2 and human IL-33 was confirmed (44). The buffer used in ST2 is 10 mM 
HEPES, pH 7.5, 150 mM NaCl, 4% glycerol. For ST2/iST2-1, 500 μM racemic iST2-1 was added to 
ST2 giving a concentration of  4% DMSO in the final buffer. For all samples, ST2 was incubated with 
iST2-1 for 1 hour at 4°C, purified through FPLC (Superdex 200), and then concentrated to 4 mg/ml. 
Serial dilution of  the samples was then performed to prepare 4 concentrations (4, 3, 2, 1 mg/ml) of  
ST2 and ST2/iST2-1. The prepared samples were shipped to SIBYLS (74) overnight. SAXS data were 
collected via the mail-in program (74, 75) using the SIBYLS beamline (12.3.1) (74) at the Advanced 
Light Source in Lawrence Berkeley National Laboratory.
The 1-dimensional buffer-subtracted SAXS profile at each protein concentration was calculated from the 
average of  20 measurements in ST2 and ST2/iST2-1 using in-house python scripts. For each protein sample, 
the SAXS profiles at different protein concentrations were inspected to exclude contribution from protein 
aggregation (caused by cumulative radiation damage) before merging to one composite SAXS profile using 
the SCÅTTER program. Using the SCÅTTER program, we calculated the Kratky plot, Rg, maximum dimen-
sion (Dmax), and P(r). The ab initio shape function derived from the P(r) was calculated by DAMMIF (76) first 
and then refined by DAMMIN (77) implemented in SCÅTTER using 13 runs to obtain the average solution. 
Although the gel data indicated the MW of our recombinant glycosylated human ST2 expressed in High Five 
cells is approximately 50 kDa, analysis of  the SAXS profile gave an estimate of  42.4 kDa.
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Cluster analysis and the pharmacophore model. A total of  1,823 compounds with 30% or greater inhibition 
from the primary screening were included in the analysis. Each compound was annotated with a bitmap 
fingerprint consisting of  166 MACCS (41) keys. Similarity indexes between 2 compounds were assigned 
by the Tanimoto coefficient (78) calculated from their fingerprints. Cutoff  values of  0.65 in similarity and 
overlap were used in the cluster analysis to classify compounds into structurally similar groups. A total 
of  1,260 groups consisting of  1–62 members were obtained. After the cluster analysis, we inspected each 
group to remove frequent binders to multiple bioassays identifiable in either PubChem or in our inter-
nal curated database. Compounds that contained substructures alerted in PAINS (42) were also excluded. 
The analysis led to selecting 45 representative compounds for the secondary dose-dependent confirmatory 
screening. The initial discovery study identified 4 confirmed hits (CD1959-0211, CB6114052, CB5107562, 
and NAT13-343201) that were used in the pharmacophore model construction. Among the 4 compounds, 
CD1959-0211 has 3 chiral centers. We have explored different stereoisomers when performing the structur-
al alignment and selected the (3aS,4S,9bS)-8-chloro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-car-
boxylic acid (shown in Supplemental Figure 1) to construct the pharmacophore model. All calculations 
and analyses were performed using the MOE program (79).
Hits enrichment based on pharmacophore searching and structure-based screening. To achieve diversity in 
hits enrichment without selecting an overwhelming number of  compounds for validation, we selected a 
4-feature pharmacophore model as a filter for searching for additional candidates from commercial com-
pound libraries using the MOE program. Besides the ligand-based pharmacophore screening, we also used 
the crystal structure of  ST2/IL-33 (PDBID: 4K3C) for structure-based screening. The ST2 structure was 
extracted from the crystal structure of  ST2/IL-33 and prepared using the Maestro suite from Schrodinger 
(80). The targeted binding site was selected at the D2 domain of  ST2 and a cavity between the D1 and D2 
domains because mutational studies (43, 81) indicated their importance to the interaction between ST2 
and IL-33. Default settings were chosen to generate the grids for performing structure-based screening of  
compound libraries using the XP docking mode in the Glide program (82) from the Maestro suite. We 
included 741 compounds of  the azaindole library from Chem-X-Infinity in the structure-based screening 
and chose 20 compounds for validation. The focus library, evaluated in our experimental assays, consists of  
118 compounds selected from the ligand-based pharmacophore search, analog searches from the vendors’ 
online tools, and in silico structure-based screening.
Microsomal stability studies. We determined the metabolic stability of  ST2 inhibitors using pooled CD-1 
mouse liver microsomes (purchased from XenoTech). Each compound at 1 μM was incubated with 0.5 
mg/ml microsomes and 1.7 mM cofactor β-NADPH in 0.1 M phosphate buffer (pH = 7.4) containing 3.3 
mM MgCl2 at 37 °C. The final solution contained less than 0.1% of  DMSO. Forty microliters of  reaction 
mixture was then taken out at 5, 10, 15, 30, 45, and 60 minutes of  incubation and the enzymatic reaction 
of  the mixture was stopped immediately by adding 3-fold excess cold acetonitrile containing 100 ng/ml of  
internal standard for quantification. Supernatant of  the collected fractions was obtained via centrifugation 
at 21,130 g for 10 minutes and used for LC–MS/MS analysis. The amount of  ST2 inhibitors not digested 
by the mouse liver microsome at each time point was then determined. We plotted the natural log of  the 
amount of  parent compound against time to calculate the half-life of  each ST2 inhibitor.
MLR. Purified CD4+ and CD8+ T cells from PBMCs of  one donor were stained with CFSE (5 μM), 
washed twice, and cultured with irradiated T cell–depleted PBMCs from another donor for 7 days in the pres-
ence of  DMSO as control or ST2 inhibitors at different concentrations in RPMI supplemented with 10% FBS, 
2 mM L-glutamine, 1% penicillin/streptomycin, 1 mM sodium pyruvate, and 50 μM β-mercaptoethanol (Life 
Technologies). Cells were collected and stained for flow cytometric analysis after 7 days of  incubation. The 
ratio of  responders to stimulators was 1:2 and no cytokines were added in the MLR.
Induction and assessment of  GVHD. Mice underwent allo-HCT as previously described (34). Briefly, in 
miHA-mismatched GVHD models (B6 → C3H.SW), C3H.SW recipient mice first received 1,100 cGy 
TBI (137Cs source) at day –1. Then, recipient mice were injected intravenously with T cell–depleted BM 
cells (5 × 106) plus splenic T cells (2 × 106) from allogeneic donors at day 0. T cells from donor mice were 
enriched by the murine CD90.2 microbead T Cell Isolation Kit (Miltenyi Biotec), and T cell–depleted BM 
was prepared with CD90.2 Microbeads (Miltenyi Biotec). In the xenogeneic GVHD model (human T cells 
→ NSG mice), irradiated (300 cGy) NSG mice were transplanted with human total T cells from PBMCs 
(1 × 106) at day 0. PBMCs were prepared from human peripheral blood Leukopacks from healthy donors 
that were purchased from the Central Indiana Blood Center under an IRB-approved protocol. PBMCs were 
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isolated and drawn by Ficoll (GE Healthcare) density gradient centrifugation. Human total T cells were 
purified using the human CD4 and CD8 Microbeads Isolation Kit (Miltenyi Biotec). Mice were housed 
in sterilized micro-isolator cages and maintained on acidified water (pH < 3) for 3 weeks. NSG mice were 
maintained on food supplemented with Uniprim and acidic water during the whole time course of  the 
experiment. Survival was monitored daily. Clinical GVHD scores were assessed weekly as described previ-
ously (83). According to animal protocols approved by the IRB, mice were euthanized when the clinical 
score reached 6.5. Recipient mice in both models received twice daily i.p. injection of  200 μl PBS with 0.5% 
DMSO as control or ST2 inhibitors for 21 days starting from day –1 to day 20 (iST2-1, 41.4 mg/kg/day; 
iST2-2, 18 mg/kg/day; and iST2-3, 20.5 mg/kg/day [in 200 μl PBS with 0.5% DMSO]). We followed the 
NIH guidelines for the care and use of  laboratory animals in this study.
Isolation of  intestinal cells. Single-cell suspensions were prepared from intestines as described previously 
(34). Briefly, intestines were flushed with PBS to remove fecal matter and mucus. Fragments (<0.5 cm) of  
intestines were digested in 10 ml DMEM containing collagenase type B (2 mg/ml; Roche), deoxyribonucle-
ase I (10 μg/ml; Roche), and 4% BSA (Sigma-Aldrich) at 37°C with shaking for 90 minutes. The digested 
mixture was then diluted with 30 ml plain DMEM, filtered through a 70-μm strainer, and centrifuged at 
850 g for 10 minutes. The cell pellets were suspended in 5 ml of  80% Percoll (GE Healthcare), overlaid 
with 8 ml of  40% Percoll, and spun at 800 g for 20 minutes at 4°C without braking. Enriched lymphocytes 
were collected from the interface. For sorting of  intestinal stem cells, we did not perform Percoll separation.
Enzyme-linked immunosorbent assay (ELISA). Plasma samples were collected from mice with GVHD 
treated with ST2 inhibitors or DMSO control. Every 7 days, human IFN-γ and human sST2 levels were 
measured from plasma of  NSG mice that received human T cells, whereas murine IFN-γ and murine sST2 
levels were measured in C3H.SW mice that received C57BL/6 BM and T cells. Levels of  human and 
murine IFN-γ were measured using the DuoSet ELISA Kit (R&D Systems); levels of  human and murine 
sST2 were measured using the Quantikine ELISA Kit (R&D Systems).
Flow cytometric analysis. Cells from MLR in vitro or isolated from intestine ex vivo were washed and prein-
cubated with purified anti-mouse CD16/CD32 mAb for 10–20 minutes at 4°C to prevent nonspecific binding 
of  the antibodies. The cells were subsequently incubated for 30 minutes at 4°C with antibodies for surface 
staining. Fixable viability dye was used to distinguish live cells from dead cells. A FoxP3/Transcription Fac-
tor Staining Buffer Set and Fixation and Permeabilization Kit were used for intracellular transcription factor 
and cytokine staining. For cytokine staining, cells were restimulated with phorbol myristate acetate (PMA; 50 
ng/ml), ionomycin (1 μg/ml; Sigma-Aldrich), and brefeldin A for 4–6 hours prior to any staining. All human 
and murine antibodies used in this work were obtained from eBioscience as shown in Supplemental Table 2.
Induction and assessment of  GVL effect. C3H.SW mice were lethally irradiated (1,100 cGy) 1 day before 
BM transplantation. Recipient mice were injected intravenously with 5 × 106 B6 BM cells and 2 × 106 
enriched B6 splenic T cells and 2 × 104 MLL-AF9 from C3H.SW background cells on day –1. Mice were 
treated intraperitoneally with iST2-1 or DMSO control at the same dosage and dosing schedule as described 
for GVHD experiments. Mice were monitored daily for survival and leukemia development and weekly for 
GVHD score assessment. We attributed death to leukemia based on a high percentage of  eGFP+ cells and 
death to GVHD only if  the mice had a low percentage of  eGFP+ cells and a high GVHD score.
Statistics. Data are shown as either means ± standard deviation (SD) from a single representative exper-
iment with triplicates or means ± standard error of  the mean (SEM) from at least 2 independent experi-
ments shown as error bars. The statistical comparisons between the treatment and control groups were 
made using unpaired t tests. For 3 groups or more, each subplot involved 2 group-wise comparisons. Prior 
to analysis, the normality assumption was examined. All tests were 2-sided at the significance level of  0.05. 
All calculations were conducted using the GraphPad Prism program version 7. A P value less than 0.05 was 
considered significant.
Study approval. Animal experiments and euthanasia protocols performed in this study were approved by 
the Indiana University School of  Medicine institutional animal care committee (IACUC protocol 11000).
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